Hallmarks of epithelial-mesenchymal plasticity in cancer - PubMed
4 hours ago
- #Cancer stem cells
- #Therapy resistance
- #Epithelial-mesenchymal plasticity
- Cancer stem cells (CSCs) drive tumor initiation, progression, metastasis, and therapy resistance via epithelial-mesenchymal plasticity (EMP), which includes EMT, hybrid E/M states, and MET.
- EMP is regulated by transcription factors, signaling pathways, non-coding RNAs, and influenced by the tumor microenvironment, with metabolic reprogramming supporting invasion and stress evasion.
- Advanced models and computational tools enable real-time tracking of EMP, mapping hybrid states, and predicting trajectories, aiding in biomarker identification.
- Therapeutic strategies targeting EMP involve pathway inhibitors, metabolic disruptors, TME modulators, and combination therapies to overcome resistance and prevent relapse.